Anika Therapeutics, Inc. Cost of Revenue
Anika Therapeutics, Inc. (ANIK) reported Cost of Revenue of $11.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-07-29
- Anika Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $11.37M, a 17.97% decline year-over-year.
- Anika Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $10.62M, a 7.59% decline year-over-year.
- Anika Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $11.44M, a 15.14% decline year-over-year.
- Anika Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $12.23M, a 20.51% increase year-over-year.
- Anika Therapeutics, Inc. cost of goods and services sold for fiscal 2025 was $49.01M, a 11.62% increase from fiscal 2024.
- Anika Therapeutics, Inc. cost of goods and services sold for fiscal 2024 was $43.91M, a 14.76% increase from fiscal 2023.
- Anika Therapeutics, Inc. cost of goods and services sold for fiscal 2023 was $38.26M, a 5.78% decline from fiscal 2022.
- Anika Therapeutics, Inc. cost of goods and services sold for fiscal 2022 was $40.61M, a 37.38% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $11.37M 10-Q · filed 2026-07-29 | $21.98M 10-Q · filed 2026-07-29 | $33.42M derived: sum of 3 quarters · filed 2026-07-29 | $45.65M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $10.62M 10-Q · filed 2026-04-30 | $22.05M derived: sum of 2 quarters · filed 2026-04-30 | $34.28M derived: sum of 3 quarters · filed 2026-04-30 | $48.14M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $11.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $23.67M derived: sum of 2 quarters · filed 2026-03-03 | $37.52M derived: sum of 3 quarters · filed 2026-07-29 | $49.01M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $12.23M 10-Q · filed 2025-11-05 | $26.09M derived: sum of 2 quarters · filed 2026-07-29 | $37.58M 10-Q · filed 2025-11-05 | $51.05M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $13.86M 10-Q · filed 2026-07-29 | $25.34M 10-Q · filed 2026-07-29 | $38.82M derived: sum of 3 quarters · filed 2026-07-29 | $48.97M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $11.49M 10-Q · filed 2026-04-30 | $24.96M derived: sum of 2 quarters · filed 2026-04-30 | $35.11M derived: sum of 3 quarters · filed 2026-04-30 | $45.35M derived: sum of 4 quarters · filed 2026-04-30 | ||||
| 2024-12-31 | $13.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $23.63M derived: sum of 2 quarters · filed 2026-03-03 | $33.86M derived: sum of 3 quarters · filed 2026-03-03 | $43.91M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $10.15M 10-Q · filed 2025-11-05 | $37.31M 10-Q · filed 2024-11-04 | $20.39M derived: sum of 2 quarters · filed 2025-11-05 | $30.43M 10-Q · filed 2025-11-05 | $67.76M 10-Q · filed 2024-11-04 | $21.76M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $10.23M 10-Q · filed 2025-07-30 | $14.56M 10-Q · filed 2024-08-08 | $20.28M 10-Q · filed 2025-07-30 | $30.45M 10-Q · filed 2024-08-08 | $11.61M derived: sum of 3 quarters · filed 2026-03-03 | $28.13M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $10.05M 10-Q · filed 2025-05-09 | $15.89M 10-Q · filed 2024-05-08 | $1.38M derived: sum of 2 quarters · filed 2026-03-03 | $17.90M derived: sum of 3 quarters · filed 2026-03-03 | $33.23M derived: sum of 4 quarters · filed 2026-03-03 | |||
| 2023-12-31 | -$8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.85M derived: sum of 2 quarters · filed 2026-03-03 | $23.18M derived: sum of 3 quarters · filed 2026-03-03 | $38.26M 10-K · filed 2026-03-03 | $63.57M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $16.52M 10-Q · filed 2024-11-04 | $31.85M derived: sum of 2 quarters · filed 2024-11-04 | $46.93M 10-Q · filed 2024-11-04 | $40.37M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-06-30 | $15.33M 10-Q · filed 2024-08-08 | $30.41M 10-Q · filed 2024-08-08 | $23.85M derived: sum of 3 quarters · filed 2025-03-17 | $41.33M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2023-03-31 | $15.08M 10-Q · filed 2024-05-08 | $8.52M derived: sum of 2 quarters · filed 2025-03-17 | $26.00M derived: sum of 3 quarters · filed 2025-03-17 | $40.80M derived: sum of 4 quarters · filed 2025-03-17 | ||||
| 2022-12-31 | -$6.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $10.92M derived: sum of 2 quarters · filed 2025-03-17 | $25.72M derived: sum of 3 quarters · filed 2025-03-17 | $40.61M 10-K · filed 2025-03-17 | $62.66M 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $17.48M 10-Q · filed 2023-11-03 | $32.28M derived: sum of 2 quarters · filed 2023-11-03 | $47.17M 10-Q · filed 2023-11-03 | $64.86M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-06-30 | $14.79M 10-Q · filed 2023-08-08 | $29.68M 10-Q · filed 2023-08-08 | $47.37M derived: sum of 3 quarters · filed 2024-03-15 | $63.88M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-03-31 | $14.89M 10-Q · filed 2023-05-09 | $32.58M derived: sum of 2 quarters · filed 2024-03-15 | $49.09M derived: sum of 3 quarters · filed 2024-03-15 | $66.42M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2021-12-31 | $17.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $34.20M derived: sum of 2 quarters · filed 2024-03-15 | $51.53M derived: sum of 3 quarters · filed 2024-03-15 | $64.85M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $16.51M 10-Q · filed 2022-11-09 | $33.85M derived: sum of 2 quarters · filed 2022-11-09 | $47.16M 10-Q · filed 2022-11-09 | $63.11M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-06-30 | $17.33M 10-Q · filed 2022-08-04 | $30.65M 10-Q · filed 2022-08-04 | $46.59M derived: sum of 3 quarters · filed 2023-03-16 | $60.95M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2021-03-31 | $13.32M 10-Q · filed 2022-05-06 | $29.26M derived: sum of 2 quarters · filed 2023-03-16 | $43.61M derived: sum of 3 quarters · filed 2023-03-16 | $60.55M derived: sum of 4 quarters · filed 2023-03-16 | ||||
| 2020-12-31 | $15.94M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $30.30M derived: sum of 2 quarters · filed 2023-03-16 | $47.23M derived: sum of 3 quarters · filed 2023-03-16 | $61.43M 10-K · filed 2023-03-16 | ||||
| 2020-09-30 | $14.35M 10-Q · filed 2021-11-05 | $31.29M derived: sum of 2 quarters · filed 2021-11-05 | $45.49M 10-Q · filed 2021-11-05 | $54.14M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $16.94M 10-Q · filed 2021-08-06 | $31.14M 10-Q · filed 2021-08-06 | $39.78M derived: sum of 3 quarters · filed 2021-08-06 | $45.74M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $14.20M 10-Q · filed 2021-05-07 | $22.85M derived: sum of 2 quarters · filed 2021-05-07 | $28.80M derived: sum of 3 quarters · filed 2021-05-07 | $35.64M derived: sum of 4 quarters · filed 2021-05-07 | ||||
| 2019-12-31 | $8.65M 10-K · filed 2020-03-06 | $14.60M derived: sum of 2 quarters · filed 2020-11-05 | $21.44M derived: sum of 3 quarters · filed 2020-11-05 | $28.75M 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | $5.95M 10-Q · filed 2020-11-05 | $12.79M derived: sum of 2 quarters · filed 2020-11-05 | $20.10M 10-Q · filed 2020-11-05 | $27.10M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $6.84M 10-Q · filed 2020-08-07 | $14.15M 10-Q · filed 2020-08-07 | $21.15M derived: sum of 3 quarters · filed 2020-08-07 | $29.43M derived: sum of 4 quarters · filed 2020-08-07 | ||||
| 2019-03-31 | $7.31M 10-Q · filed 2020-05-22 | $14.31M derived: sum of 2 quarters · filed 2020-05-22 | $22.59M derived: sum of 3 quarters · filed 2020-05-22 | $30.75M derived: sum of 4 quarters · filed 2020-05-22 | ||||
| 2018-12-31 | $7.00M 10-K · filed 2020-03-06 | $15.28M derived: sum of 2 quarters · filed 2020-03-06 | $23.43M derived: sum of 3 quarters · filed 2020-03-06 | $31.28M 10-K/A · filed 2021-04-26 | ||||
| 2018-09-30 | $8.28M 10-K · filed 2020-03-06 | $16.43M derived: sum of 2 quarters · filed 2020-03-06 | $24.28M 10-Q · filed 2019-10-28 | $32.99M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2018-06-30 | $8.15M 10-K · filed 2020-03-06 | $16.00M 10-Q · filed 2019-07-26 | $24.71M derived: sum of 3 quarters · filed 2020-03-06 | $30.96M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2018-03-31 | $7.84M 10-K · filed 2020-03-06 | $16.56M derived: sum of 2 quarters · filed 2020-03-06 | $22.81M derived: sum of 3 quarters · filed 2020-03-06 | $29.13M derived: sum of 4 quarters · filed 2020-03-06 | ||||
| 2017-12-31 | $8.72M 10-K · filed 2019-02-27 | $14.97M derived: sum of 2 quarters · filed 2019-02-27 | $21.28M derived: sum of 3 quarters · filed 2019-02-27 | $27.36M 10-K · filed 2020-03-06 | ||||
| 2017-09-30 | $6.25M 10-K · filed 2019-02-27 | $12.56M derived: sum of 2 quarters · filed 2019-02-27 | $18.65M 10-Q · filed 2018-10-26 | |||||
| 2017-06-30 | $6.32M 10-K · filed 2019-02-27 | $12.40M 10-Q · filed 2018-07-31 | ||||||
| 2017-03-31 | $6.08M 10-K · filed 2019-02-27 | |||||||
| 2016-12-31 | $24.03M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |